| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Fox Chase Cancer Center, Philadelphia, PA, USA
* To whom correspondence should be addressed. E-mail: EP_Henske{at}fccc.edu.
Lymphangiomyomatosis (LAM) is a progressive lung disease affecting almost exclusively women. The reasons for this strong gender predisposition are poorly understood. Renal angiomyolipomas occur in 50-60% of sporadic LAM patients. The smooth muscle cells of pulmonary LAM and renal angiomyolipomas are nearly indistinguishable morphologically. Here, we report the first successful cell culture of a LAM-associated renal angiomyolipoma. The cells carried inactivating mutations in both alleles of the TSC2 gene, and expressed estrogen receptor alpha, estrogen receptor beta, and androgen receptor. To elucidate the cellular pathways through which steroid hormones influence LAM pathogenesis, we treated the cells with both estradiol and tamoxifen. Cell growth was stimulated by estradiol, associated with phosphorylation of p44/42 MAPK at 5 min and an increase in c-myc expression at 4 hrs. Tamoxifen citrate also stimulated cell growth, associated with increased phosphorylation of p44/42 MAPK and expression of c-myc, indicating that tamoxifen has agonist effects on angiomyolipoma cells. This response to tamoxifen in human angiomyolipoma cells differs from prior studies of Eker rat leiomyoma cells, possibly reflecting cell type or species differences in cells lacking tuberin. Our data provide the first evidence that estradiol stimulates the growth of angiomyolipoma cells, that tamoxifen has agonist effects in angiomyolipoma cells, and that estradiol and tamoxifen impact both genomic and nongenomic signaling pathways in angiomyolipoma cells. The responsiveness of angiomyolipoma cells to estradiol may be related to the underlying reasons that lymphangiomyomatosis affects primarily women.
This article has been cited by other articles:
|
|
 |
|
  R. B. Issaka, S. Oommen, S. K. Gupta, G. Liu, J. L. Myers, J. H. Ryu, and N. E. Vlahakis Vascular Endothelial Growth Factors C and D Induces Proliferation of Lymphangioleiomyomatosis Cells through Autocrine Crosstalk with Endothelium Am. J. Pathol., October 1, 2009; 175(4): 1410 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Clements, S. L Asprey, T. A McCulloch, T. A Morris, S. A Watson, and S. R Johnson Analysis of the oestrogen response in an angiomyolipoma derived xenograft model Endocr. Relat. Cancer, March 1, 2009; 16(1): 59 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Yu, V. A. Robb, T. A. Morrison, E. A. Ariazi, M. Karbowniczek, A. Astrinidis, C. Wang, L. Hernandez-Cuebas, L. F. Seeholzer, E. Nicolas, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells PNAS, February 24, 2009; 106(8): 2635 - 2640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Yun, M. Y. Lee, J. M. Ryu, C. H. Song, and H. J. Han Role of HIF-1{alpha} and VEGF in human mesenchymal stem cell proliferation by 17{beta}-estradiol: involvement of PKC, PI3K/Akt, and MAPKs Am J Physiol Cell Physiol, February 1, 2009; 296(2): C317 - C326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. X. McCormack Lymphangioleiomyomatosis*: A Clinical Update Chest, February 1, 2008; 133(2): 507 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Schwartz, A. S. Wenzlaff, G. M. Prysak, V. Murphy, M. L. Cote, S. C. Brooks, D. F. Skafar, and F. Lonardo Reproductive Factors, Hormone Use, Estrogen Receptor Expression and Risk of Non Small-Cell Lung Cancer in Women J. Clin. Oncol., December 20, 2007; 25(36): 5785 - 5792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Juvet, F. X. McCormack, D. J. Kwiatkowski, and G. P. Downey Molecular Pathogenesis of Lymphangioleiomyomatosis: Lessons Learned from Orphans Am. J. Respir. Cell Mol. Biol., April 1, 2007; 36(4): 398 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zarogiannis, C. Hatzoglou, P. A. Molyvdas, and K. Gourgoulianis Lymphangioleiomyomatosis Eur. Respir. J., December 1, 2006; 28(6): 1284 - 1284. [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Schwartz, G. M. Prysak, V. Murphy, F. Lonardo, H. Pass, J. Schwartz, and S. Brooks Nuclear Estrogen Receptor {beta} in Lung Cancer: Expression and Survival Differences by Sex Clin. Cancer Res., October 15, 2005; 11(20): 7280 - 7287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Black, Q. Ge, S. Boustany, P. R. A. Johnson, M. H. Poniris, A. R. Glanville, B. G. G. Oliver, L. M. Moir, and J. K. Burgess In vitro studies of lymphangioleiomyomatosis Eur. Respir. J., October 1, 2005; 26(4): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Finlay The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L690 - L693. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
